Real-time Estimate
Cboe BZX
10:33:01 2024-04-29 am EDT
|
5-day change
|
1st Jan Change
|
1.035
USD
|
-0.49%
|
|
+2.48%
|
-49.51%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
10.52
|
12.06
|
6.993
|
119.7
|
12.41
|
8.32
|
Enterprise Value (EV)
1 |
9.758
|
12.1
|
7.924
|
121.5
|
11.82
|
12.13
|
P/E ratio
|
-7.19
x
|
-7.57
x
|
-4.78
x
|
-24.5
x
|
-0.6
x
|
-0.61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
135
x
|
1,028
x
|
422
x
|
201
x
|
3.53
x
|
68.1
x
|
EV / Revenue
|
126
x
|
1,031
x
|
478
x
|
204
x
|
3.36
x
|
99.3
x
|
EV / EBITDA
|
-7.63
x
|
-7.77
x
|
-5.56
x
|
-66.7
x
|
-1.29
x
|
-1.51
x
|
EV / FCF
|
-7.2
x
|
-23.8
x
|
-14.3
x
|
4.66
x
|
-0.48
x
|
12.8
x
|
FCF Yield
|
-13.9%
|
-4.19%
|
-7.01%
|
21.4%
|
-207%
|
7.82%
|
Price to Book
|
14.5
x
|
-77.6
x
|
-8.53
x
|
11.9
x
|
0.36
x
|
0.39
x
|
Nbr of stocks (in thousands)
|
520
|
536
|
548
|
1,899
|
4,002
|
4,059
|
Reference price
2 |
20.25
|
22.50
|
12.76
|
63.00
|
3.100
|
2.050
|
Announcement Date
|
4/16/19
|
3/30/20
|
3/30/21
|
3/21/22
|
4/3/23
|
3/8/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.0777
|
0.0117
|
0.0166
|
0.5946
|
3.52
|
0.1221
|
EBITDA
1 |
-1.278
|
-1.558
|
-1.426
|
-1.823
|
-9.143
|
-8.049
|
EBIT
1 |
-1.335
|
-1.58
|
-1.44
|
-3.867
|
-13.98
|
-12.92
|
Operating Margin
|
-1,717.2%
|
-13,472.11%
|
-8,696.7%
|
-650.47%
|
-397.09%
|
-10,580.14%
|
Earnings before Tax (EBT)
1 |
-1.339
|
-1.581
|
-1.451
|
-3.889
|
-14.01
|
-13.77
|
Net income
1 |
-1.339
|
-1.581
|
-1.451
|
-3.889
|
-14.01
|
-13.77
|
Net margin
|
-1,722.3%
|
-13,479.65%
|
-8,758.21%
|
-654.04%
|
-397.96%
|
-11,276.98%
|
EPS
2 |
-2.817
|
-2.973
|
-2.671
|
-2.575
|
-5.135
|
-3.360
|
Free Cash Flow
1 |
-1.356
|
-0.5074
|
-0.5558
|
26.07
|
-24.47
|
0.9486
|
FCF margin
|
-1,744.86%
|
-4,324.94%
|
-3,355.68%
|
4,384.31%
|
-695.13%
|
776.86%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/16/19
|
3/30/20
|
3/30/21
|
3/21/22
|
4/3/23
|
3/8/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
0.04
|
0.93
|
1.87
|
-
|
3.81
|
Net Cash position
1 |
0.76
|
-
|
-
|
-
|
0.58
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.0228
x
|
-0.6528
x
|
-1.025
x
|
-
|
-0.4731
x
|
Free Cash Flow
1 |
-1.36
|
-0.51
|
-0.56
|
26.1
|
-24.5
|
0.95
|
ROE (net income / shareholders' equity)
|
-223%
|
-552%
|
292%
|
-83.1%
|
-62.5%
|
-46.6%
|
ROA (Net income/ Total Assets)
|
-44.4%
|
-95.9%
|
-210%
|
-11.8%
|
-22.4%
|
-23.4%
|
Assets
1 |
3.015
|
1.649
|
0.6904
|
33.05
|
62.48
|
58.79
|
Book Value Per Share
2 |
1.400
|
-0.2900
|
-1.490
|
5.300
|
8.650
|
5.230
|
Cash Flow per Share
2 |
2.450
|
0.7600
|
0.0400
|
0.9100
|
0.4600
|
0.4000
|
Capex
1 |
0
|
0
|
-
|
0.14
|
0.63
|
0.09
|
Capex / Sales
|
6.31%
|
13.96%
|
-
|
24.18%
|
18.01%
|
76.15%
|
Announcement Date
|
4/16/19
|
3/30/20
|
3/30/21
|
3/21/22
|
4/3/23
|
3/8/24
|
|
1st Jan change
|
Capi.
|
---|
| -49.51% | 6.19M | | -2.04% | 103B | | +1.62% | 95.28B | | +3.20% | 22.15B | | -16.16% | 21.02B | | -8.38% | 18.15B | | -41.01% | 16.73B | | -14.89% | 16.05B | | +4.46% | 13.68B | | +34.26% | 12.17B |
Bio Therapeutic Drugs
|